×
About 3,247 results

ALLMedicine™ Hypopituitarism Center

Research & Reviews  1,559 results

Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
https://doi.org/10.1016/j.currproblcancer.2021.100710
Current Problems in Cancer; Nogueira E, Menon A et. al.

Feb 24th, 2021 - Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostl...

Psychological well-being and illness perceptions in patients with hypopituitarism.
https://doi.org/10.1007/s11102-021-01131-w 10.1016/0301-0082(94)90014-0 10.1210/endo.132.5.8477671 10.1016/0165-3806(93)90008-X 10.1016/j.jns.2010.11.027 10.1007/s11011-017-0076-3 10.1002/cne.902940107 10.1016/j.exger.2014.10.002 10.1586/14737167.2014.963559 10.1111/j.1365-2265.2010.03947.x 10.1159/000012276 10.1210/jcem.83.2.4594 10.1016/0306-4530(95)00050-X 10.1111/and.12199 10.1016/S0140-6736(07)60673-4 10.1016/j.psyneuen.2004.10.002 10.1159/000093337 10.1016/j.ghir.2004.11.004 10.1159/000127099 10.1186/1477-7525-3-63 10.1210/jc.2005-2596 10.1210/jcem.82.6.3988 10.1530/EJE-14-0515 10.1007/s11102-014-0561-1 10.2165/00019053-200017060-00008 10.1371/journal.pone.0060041 10.1002/edm2.165 10.1210/jc.2009-2032 10.1210/jc.2004-1375 10.1210/jc.2010-2742 10.1097/MED.0000000000000265 10.1016/B978-0-444-53702-7.00007-5 10.1210/jc.2010-0512 10.1210/jc.2010-1253 10.1210/jc.2004-0669 10.1210/jc.2006-0003 10.1530/EJE-07-0259 10.1530/EJE-13-0471 10.1530/EJE-14-1101 10.1016/j.nicl.2014.01.017 10.1007/BF02090456 10.1037/0021-843X.87.1.49 10.1177/0146167292186007 10.1210/jc.2011-1645 10.1530/EJE-11-0307 10.1080/08870440290001502 10.1097/ACI.0b013e32833950c1 10.1097/00006842-200207000-00007 10.1177/1474515113481908 10.2147/COPD.S109227 10.1186/s12955-018-0963-2 10.1111/j.1600-0447.1983.tb09716.x 10.1007/s11136-014-0763-z 10.1192/bjp.180.5.461 10.1016/j.comppsych.2012.03.014 10.1016/j.math.2012.03.001 10.1016/j.jpsychores.2005.10.020 10.1001/archneur.1996.00550070080014 10.1016/S0140-6736(16)30053-8 10.1007/s12020-016-1211-3
Pituitary Slagboom TNA, Deijen JB et. al.

Feb 19th, 2021 - The primary aim of the current study was to objectify a spectrum of persisting subjective psychological complaints in patients with hypopituitarism, at least six months after normalizing of the hormonal disturbances. Also, gender differences on th...

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Imp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814954
Canadian Journal of Gastroenterology & Hepatology; Singeap AM, Stanciu C et. al.

Jan 28th, 2021 - Nonalcoholic fatty liver disease (NAFLD) has a rising prevalence worldwide. Its potential for evolution towards liver cirrhosis and hepatocellular carcinoma, as well as associations with extrahepatic manifestations, represents a double burden for ...

Primary Pituitary Lymphoma As Rare Cause Of A Pituitary Mass And Hypopituitarism In Adu...
https://doi.org/10.4158/EP-2020-0286
Endocrine Practice : Official Journal of the American Col... Caputo M, Prencipe N et. al.

Jan 20th, 2021 - Differential diagnosis of nonadenomatous sellar masses causing hypopituitarism is still a challenge. Among these masses, growing evidence has demonstrated that primary pituitary lymphoma is a specific and emerging entity. The aim of our study was ...

Biological Effective Dose as a Predictor of Hypopituitarism After Single-Fraction Pitui...
https://doi.org/10.1093/neuros/nyaa555
Neurosurgery Graffeo CS, Perry A et. al.

Jan 20th, 2021 - Hypopituitarism is the most frequent complication after pituitary adenoma stereotactic radiosurgery (SRS) and is correlated with increasing radiation to the pituitary gland. Biological effective dose (BED) is a dosimetric parameter that incorporat...

see more →

Guidelines  7 results

Management of immune-related adverse events in endocrine organs induced by immune check...
https://doi.org/10.1507/endocrj.EJ19-0163
Endocrine Journal; Arima H, Iwama S et. al.

Jun 27th, 2019 - Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve,...

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practi...
https://doi.org/10.1210/jc.2016-2118
The Journal of Clinical Endocrinology and Metabolism; Fleseriu M, Hashim IA et. al.

Nov 4th, 2016 - To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults. The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer. The American Association for...

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Gu...
https://academic.oup.com/jcem/article/101/11/3888/2764912
Fleseriu, M.

Oct 31st, 2016 - To formulate clinical practice guidelines for hormonal replacement in hypopituitarism in adults. The participants include an Endocrine Society-appointed Task Force of six experts, a methodologist, and a medical writer.

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pri...
https://doi.org/10.1227/NEU.0000000000001389
Neurosurgery Lucas JW, Bodach ME et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present clinically with vision loss and hypopituitarism. To characterize the existing literature as it pertains to the initial management of NFPAs. A sys...

see more →

Clinicaltrials.gov  1,621 results

Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
https://doi.org/10.1016/j.currproblcancer.2021.100710
Current Problems in Cancer; Nogueira E, Menon A et. al.

Feb 24th, 2021 - Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostl...

Psychological well-being and illness perceptions in patients with hypopituitarism.
https://doi.org/10.1007/s11102-021-01131-w 10.1016/0301-0082(94)90014-0 10.1210/endo.132.5.8477671 10.1016/0165-3806(93)90008-X 10.1016/j.jns.2010.11.027 10.1007/s11011-017-0076-3 10.1002/cne.902940107 10.1016/j.exger.2014.10.002 10.1586/14737167.2014.963559 10.1111/j.1365-2265.2010.03947.x 10.1159/000012276 10.1210/jcem.83.2.4594 10.1016/0306-4530(95)00050-X 10.1111/and.12199 10.1016/S0140-6736(07)60673-4 10.1016/j.psyneuen.2004.10.002 10.1159/000093337 10.1016/j.ghir.2004.11.004 10.1159/000127099 10.1186/1477-7525-3-63 10.1210/jc.2005-2596 10.1210/jcem.82.6.3988 10.1530/EJE-14-0515 10.1007/s11102-014-0561-1 10.2165/00019053-200017060-00008 10.1371/journal.pone.0060041 10.1002/edm2.165 10.1210/jc.2009-2032 10.1210/jc.2004-1375 10.1210/jc.2010-2742 10.1097/MED.0000000000000265 10.1016/B978-0-444-53702-7.00007-5 10.1210/jc.2010-0512 10.1210/jc.2010-1253 10.1210/jc.2004-0669 10.1210/jc.2006-0003 10.1530/EJE-07-0259 10.1530/EJE-13-0471 10.1530/EJE-14-1101 10.1016/j.nicl.2014.01.017 10.1007/BF02090456 10.1037/0021-843X.87.1.49 10.1177/0146167292186007 10.1210/jc.2011-1645 10.1530/EJE-11-0307 10.1080/08870440290001502 10.1097/ACI.0b013e32833950c1 10.1097/00006842-200207000-00007 10.1177/1474515113481908 10.2147/COPD.S109227 10.1186/s12955-018-0963-2 10.1111/j.1600-0447.1983.tb09716.x 10.1007/s11136-014-0763-z 10.1192/bjp.180.5.461 10.1016/j.comppsych.2012.03.014 10.1016/j.math.2012.03.001 10.1016/j.jpsychores.2005.10.020 10.1001/archneur.1996.00550070080014 10.1016/S0140-6736(16)30053-8 10.1007/s12020-016-1211-3
Pituitary Slagboom TNA, Deijen JB et. al.

Feb 19th, 2021 - The primary aim of the current study was to objectify a spectrum of persisting subjective psychological complaints in patients with hypopituitarism, at least six months after normalizing of the hormonal disturbances. Also, gender differences on th...

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Imp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814954
Canadian Journal of Gastroenterology & Hepatology; Singeap AM, Stanciu C et. al.

Jan 28th, 2021 - Nonalcoholic fatty liver disease (NAFLD) has a rising prevalence worldwide. Its potential for evolution towards liver cirrhosis and hepatocellular carcinoma, as well as associations with extrahepatic manifestations, represents a double burden for ...

Primary Pituitary Lymphoma As Rare Cause Of A Pituitary Mass And Hypopituitarism In Adu...
https://doi.org/10.4158/EP-2020-0286
Endocrine Practice : Official Journal of the American Col... Caputo M, Prencipe N et. al.

Jan 20th, 2021 - Differential diagnosis of nonadenomatous sellar masses causing hypopituitarism is still a challenge. Among these masses, growing evidence has demonstrated that primary pituitary lymphoma is a specific and emerging entity. The aim of our study was ...

Biological Effective Dose as a Predictor of Hypopituitarism After Single-Fraction Pitui...
https://doi.org/10.1093/neuros/nyaa555
Neurosurgery Graffeo CS, Perry A et. al.

Jan 20th, 2021 - Hypopituitarism is the most frequent complication after pituitary adenoma stereotactic radiosurgery (SRS) and is correlated with increasing radiation to the pituitary gland. Biological effective dose (BED) is a dosimetric parameter that incorporat...

see more →

News  49 results

Pituitary Hormones Should Be 'Restored to Healthy Levels'
https://www.medscape.com/viewarticle/870650

Oct 19th, 2016 - Patients with hypopituitarism should have their hormone levels restored as close to physiologic levels as possible, while taking into account potential interactions between hormones and other medications, say new guidelines on diagnosing and manag...

Fast Five Quiz: How Much Do You Know About Depression?
https://reference.medscape.com/viewarticle/857435_5

Jan 19th, 2016 - Neuroimaging can help clarify the nature of the neurologic illness that may produce psychiatric symptoms, but these studies are costly and may be of questionable value in patients without discrete neurologic deficits. CT scanning or MRI of the bra...

AACE: Endocrine treatment of childhood cancer survivors needs improvement
https://www.mdedge.com/internalmedicine/article/100131/pituitary-thyroid-adrenal-disorders/aace-endocrine-treatment
Deepak Chitnis

Jun 2nd, 2015 - NASHVILLE – Endocrinologists dealing with adult patients who survived cancer during childhood should ensure that they have an adequate understanding of the elevated risk that such patients are at for various endocrine conditions, such as hypogonad.

New guidelines address hypopituitarism in TBI
https://www.mdedge.com/neurology/article/99590/pituitary-thyroid-adrenal-disorders/new-guidelines-address-hypopituitarism
Jennie Smith

May 12th, 2015 - New guidelines on traumatic brain injury and neuroendocrine dysfunction ask clinicians to be mindful that hypopituitarism in TBI survivors can develop following injuries classified as mild and can be slow to develop. The guidelines – published onl.

see more →

Patient Education  11 results see all →